enVista Envy hydrophobic acrylic intraocular lens (IOL), enVista Envy toric hydrophobic acrylic intraocular lens (IOL)
Bausch + Lomb, Inc. · Decision date Jul 30, 2025
What did the FDA approve?
FDA records P240005/S003 as a supplement to PMA P240005, with the supplement type “135 Review Track For 30-Day Notice”. The recorded decision is approval, dated Jul 30, 2025.
FDA approval order statement
approval for a replacement of the optical metrology platform for dioptric power and image quality inspection of enVista Envy and enVista Envy Toric Hydrophobic Acrylic Intraocular Lenses
- Regulatory pathway
- PMA supplement
- Supplement type
- 135 Review Track For 30-Day Notice
- Clinical specialty
- Ophthalmic
- Decision date
- Jul 30, 2025
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P240005/S003
- Regulatory pathway
- PMA supplement
- Applicant
- Bausch + Lomb, Inc.
- Product code
- MFK
- Decision code
- APPR
- Decision date
- Jul 30, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Lens, multifocal intraocular.
- Applicant
- Bausch + Lomb, Inc.
- Product code
- MFK
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P240005. Subsequent supplements may change the device or its indications.
FDA decision timeline
P240005 · Original PMA
enVista Envy hydrophobic acrylic intraocular lens (IOL), enVista Envy toric hydrophobic acrylic intraocular lens (IOL)
P240005/S003 received
Application receipt date recorded by FDA.
P240005/S003 · FDA decision
135 Review Track For 30-Day Notice
P240005/S006 · Related supplement
enVista Envy Hydrophobic Acrylic Intraocular Lens
P240005/S005 · Related supplement
enVista Envy hydrophobic acrylic intraocular lens (IOL), enVista Envy toric hydrophobic acrylic intraocular lens (IOL)
P240005/S007 · Related supplement
enVista Envy hydrophobic acrylic intraocular lens (IOL)
P240005/S008 · Related supplement
enVista Envy Hydrophobic Acrylic Intraocular Lens
P240005/S009 · Related supplement
enVista Envy Hydrophobic Acrylic Intraocular Lens
P240005/S010 · Related supplement
enVista Envy Hydrophobic Acrylic Intraocular Lens
Timeline entries are records held by MedtechLedger for P240005. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P240005
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Bausch + Lomb, Inc. | PMA approval | Oct 10, 2024 | FDA | |
| Bausch + Lomb, Inc. | PMA supplement | Jul 22, 2026 | FDA | |
| Bausch + Lomb, Inc. | PMA supplement | Aug 12, 2026 | FDA | |
| Bausch + Lomb, Inc. | PMA supplement | Sep 3, 2026 | FDA | |
| Bausch + Lomb, Inc. | PMA supplement | Sep 30, 2026 | FDA | |
| Bausch + Lomb, Inc. | PMA supplement | Oct 14, 2026 | FDA | |
| Bausch + Lomb, Inc. | PMA supplement | Oct 23, 2026 | FDA |
Explore the linked device profile
Other records with product code MFK
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
ClearView HD intraocular lens (IOL)P200020/S013 | Lenstec, Inc. | PMA supplement | Oct 23, 2026 | FDA |
TECNIS Multi-focal 3-pc, Model ZMA00P080010/S032 | Johnson & Johnson Surgical Vision, Inc. | PMA supplement | Oct 19, 2026 | FDA |
| Rayner Intraocular Lenses , Ltd. | PMA supplement | Sep 24, 2026 | FDA | |
| Alcon Research, Ltd. | PMA supplement | Jul 6, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Bausch + Lomb, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 1400 N. Goodman St., Rochester, NY, 14609
Sources and methodology
- Original FDA record: P240005/S003
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records





